IMMUNICON AND PFIZER EXTEND AND EXPAND CLINICAL RESEARCH AND DEVELOPMENT AGREEMENT

Immunicon Corporation announced today an extension of its Research and Development Agreement with Pfizer, Inc., under which the Company collaborates with Pfizer to develop new reagents designed to detect certain undisclosed antigens on circulating tumor cells (CTCs). The collaboration began in February2003 and is now amended to permit the parties to initiate new clinical research studies by adding new Appendices duly signed by both parties to the Agreement.
Finanzen.net